Epitalon

Research-Grade

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, developed by Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of Epithalamin — a polypeptide extract derived from the pineal gland of young animals. The foundational concept behind Epitalon is Khavinson's bioregulator peptide theory: that short peptides (2-4 amino acids) can modulate specific gene-expression patterns in target tissues, and that age-related peptide depletion contributes to organ-specific functional decline. Epitalon's primary documented mechanism is upregulation of telomerase reverse transcriptase (TERT) gene expression, the catalytic subunit of the telomerase enzyme that maintains telomere length. In human somatic cell cultures, Epitalon has been shown to reactivate telomerase activity and induce telomere elongation — an effect confirmed in vitro by Khavinson's group. It is critical to distinguish, however, between telomerase activation (increased enzyme activity) and sustained telomere lengthening in vivo, which requires repeated or chronic telomerase upregulation and has not been conclusively demonstrated in independent human studies. Beyond telomerase, Epitalon has been reported to restore melatonin secretion in aging individuals — the pineal gland's melatonin output declines substantially with age, and Khavinson's cohort studies documented normalization of evening melatonin peaks following Epitalon courses. This pineal bioregulatory effect may contribute to improved circadian rhythm function and sleep quality in elderly subjects. Multi-year observational studies conducted in Russian institutional elderly cohorts reported reductions in all-cause mortality and cardiovascular events, though these studies are small by Western standards, originate from a single research center, and have not been independently replicated. The broader context of Russian gerontology research — including decades of work on organ-specific bioregulator peptides for thymus, retina, prostate, and other tissues — provides the intellectual framework for Epitalon, but this entire field remains largely outside mainstream Western peer-review channels. Epitalon is administered as short pulsed subcutaneous courses (5-10 mg daily for 10-20 days, repeated 2-3 times per year) and is classified as a research peptide globally with no regulatory approval in any jurisdiction, though it is widely adopted in off-label longevity practice.